Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 Sep 15:S2152-2650(23)01551-3. doi: 10.1016/j.clml.2023.09.004. Online ahead of print.ABSTRACTBlack and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a 1-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, nonprofits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivit...
Source: Clinical Lymphoma and Myeloma - October 2, 2023 Category: Cancer & Oncology Authors: Monique Hartley-Brown Craig E Cole Pamela Price Michael Andreini George Mulligan Anne Quinn Young Hearn Jay Cho Source Type: research
Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
CONCLUSIONS: Our results suggest that the ALP levels after CAR-T therapy could serve as a suitable biomarker for monitoring CAR-T cell proliferation, CRS grading, and prognosis in patients with MM.PMID:37777383 | DOI:10.1016/j.clml.2023.08.017 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 30, 2023 Category: Cancer & Oncology Authors: Rujiao Dong Yudi Wang Xiaohong Sun Yuanyuan Lin Yuqing Luo Chongyun Xing Lan Sun Shenghui Zhang Kang Yu Songfu Jiang Yi Chen Source Type: research
Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
CONCLUSIONS: Our results suggest that the ALP levels after CAR-T therapy could serve as a suitable biomarker for monitoring CAR-T cell proliferation, CRS grading, and prognosis in patients with MM.PMID:37777383 | DOI:10.1016/j.clml.2023.08.017 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 30, 2023 Category: Cancer & Oncology Authors: Rujiao Dong Yudi Wang Xiaohong Sun Yuanyuan Lin Yuqing Luo Chongyun Xing Lan Sun Shenghui Zhang Kang Yu Songfu Jiang Yi Chen Source Type: research
Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
CONCLUSIONS: Our results suggest that the ALP levels after CAR-T therapy could serve as a suitable biomarker for monitoring CAR-T cell proliferation, CRS grading, and prognosis in patients with MM.PMID:37777383 | DOI:10.1016/j.clml.2023.08.017 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 30, 2023 Category: Cancer & Oncology Authors: Rujiao Dong Yudi Wang Xiaohong Sun Yuanyuan Lin Yuqing Luo Chongyun Xing Lan Sun Shenghui Zhang Kang Yu Songfu Jiang Yi Chen Source Type: research
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
CONCLUSION: Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.PMID:37743180 | DOI:10.1016/j.clml.2023.08.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Sundar Jagannath Sosana Delimpasi Sebastian Grosicki Dane R Van Domelen Ohad S Bentur Ivan Špička Meletios A Dimopoulos Source Type: research
Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients treated in the VA have received therapies in line with current evidence-based treatment practices over the past 20 years. Treatment with targeted therapies is associated with longer median OS both in the first line and relapsed/refractory setting.PMID:37743181 | DOI:10.1016/j.clml.2023.09.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Helen Ma Susan O'Brien Pankaj Gupta Source Type: research
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
CONCLUSION: Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.PMID:37743180 | DOI:10.1016/j.clml.2023.08.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Sundar Jagannath Sosana Delimpasi Sebastian Grosicki Dane R Van Domelen Ohad S Bentur Ivan Špička Meletios A Dimopoulos Source Type: research
Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients treated in the VA have received therapies in line with current evidence-based treatment practices over the past 20 years. Treatment with targeted therapies is associated with longer median OS both in the first line and relapsed/refractory setting.PMID:37743181 | DOI:10.1016/j.clml.2023.09.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Helen Ma Susan O'Brien Pankaj Gupta Source Type: research
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
CONCLUSION: Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.PMID:37743180 | DOI:10.1016/j.clml.2023.08.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Sundar Jagannath Sosana Delimpasi Sebastian Grosicki Dane R Van Domelen Ohad S Bentur Ivan Špička Meletios A Dimopoulos Source Type: research
Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients treated in the VA have received therapies in line with current evidence-based treatment practices over the past 20 years. Treatment with targeted therapies is associated with longer median OS both in the first line and relapsed/refractory setting.PMID:37743181 | DOI:10.1016/j.clml.2023.09.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Helen Ma Susan O'Brien Pankaj Gupta Source Type: research
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
CONCLUSION: Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.PMID:37743180 | DOI:10.1016/j.clml.2023.08.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Sundar Jagannath Sosana Delimpasi Sebastian Grosicki Dane R Van Domelen Ohad S Bentur Ivan Špička Meletios A Dimopoulos Source Type: research
Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients treated in the VA have received therapies in line with current evidence-based treatment practices over the past 20 years. Treatment with targeted therapies is associated with longer median OS both in the first line and relapsed/refractory setting.PMID:37743181 | DOI:10.1016/j.clml.2023.09.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Helen Ma Susan O'Brien Pankaj Gupta Source Type: research
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
CONCLUSION: Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.PMID:37743180 | DOI:10.1016/j.clml.2023.08.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Sundar Jagannath Sosana Delimpasi Sebastian Grosicki Dane R Van Domelen Ohad S Bentur Ivan Špička Meletios A Dimopoulos Source Type: research
Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients treated in the VA have received therapies in line with current evidence-based treatment practices over the past 20 years. Treatment with targeted therapies is associated with longer median OS both in the first line and relapsed/refractory setting.PMID:37743181 | DOI:10.1016/j.clml.2023.09.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 24, 2023 Category: Cancer & Oncology Authors: Helen Ma Susan O'Brien Pankaj Gupta Source Type: research
Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma - The Oregon Health and Science University Experience
CONCLUSION: Our experience with HCT for PTCL shows that HCT has acceptable toxicities and relatively long disease remissions. AutoHCT was most frequently utilized as planned remission consolidation while alloHCT was most often used late during salvage. Differences in response between autoHCT and alloHCT likely reflect differences in clinical setting and underlying disease natural history and biology.PMID:37741763 | DOI:10.1016/j.clml.2023.08.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 23, 2023 Category: Cancer & Oncology Authors: Derek Galligan Staci Williamson Jessie Myers Andy I Chen Brandon Hayes-Lattin Craig Okada Stephen Spurgeon Richard Maziarz Levanto Schachter Source Type: research
